Le Audrey P, Huang Yong, Pingle Sandeep C, Kesari Santosh, Wang Huaien, Yong Raymund L, Zou Hongyan, Friedel Roland H
Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Translational Neuro-Oncology Laboratories, Moores UCSD Cancer Center and Department of Neurosciences, La Jolla, CA, USA.
Oncotarget. 2015 Mar 30;6(9):7293-304. doi: 10.18632/oncotarget.3421.
Invasive growth is a major determinant of the high lethality of malignant gliomas. Plexin-B2, an axon guidance receptor important for mediating neural progenitor cell migration during development, is upregulated in gliomas, but its function therein remains poorly understood. Combining bioinformatic analyses, immunoblotting and immunohistochemistry of patient samples, we demonstrate that Plexin-B2 is consistently upregulated in all types of human gliomas and that its expression levels correlate with glioma grade and poor survival. Activation of Plexin-B2 by Sema4C ligand in glioblastoma cells induced actin-based cytoskeletal dynamics and invasive migration in vitro. This proinvasive effect was associated with activation of the cell motility mediators RhoA and Rac1. Furthermore, costimulation of Plexin-B2 and the receptor tyrosine kinase Met led to synergistic Met phosphorylation. In intracranial glioblastoma transplants, Plexin-B2 knockdown hindered invasive growth and perivascular spreading, and resulted in decreased tumor vascularity. Our results demonstrate that Plexin-B2 promotes glioma invasion and vascularization, and they identify Plexin-B2 as a potential novel prognostic marker for glioma malignancy. Targeting the Plexin-B2 pathway may represent a novel therapeutic approach to curtail invasive growth of glioblastoma.
侵袭性生长是恶性胶质瘤高致死率的主要决定因素。丛状蛋白-B2是一种轴突导向受体,在发育过程中对介导神经祖细胞迁移很重要,在胶质瘤中上调,但其在其中的功能仍知之甚少。结合生物信息学分析、患者样本的免疫印迹和免疫组化,我们证明丛状蛋白-B2在所有类型的人类胶质瘤中均持续上调,且其表达水平与胶质瘤分级及不良预后相关。胶质母细胞瘤细胞中Sema4C配体激活丛状蛋白-B2可诱导基于肌动蛋白的细胞骨架动力学变化及体外侵袭性迁移。这种促侵袭作用与细胞运动介质RhoA和Rac1的激活有关。此外,丛状蛋白-B2与受体酪氨酸激酶Met的共刺激导致Met协同磷酸化。在颅内胶质母细胞瘤移植中,丛状蛋白-B2敲低可阻碍侵袭性生长和血管周围扩散,并导致肿瘤血管生成减少。我们的结果表明丛状蛋白-B2促进胶质瘤侵袭和血管生成,并将丛状蛋白-B2确定为胶质瘤恶性程度的一种潜在新型预后标志物。靶向丛状蛋白-B2通路可能代表一种抑制胶质母细胞瘤侵袭性生长的新型治疗方法。